The Antifolates

Hematology/Oncology Clinics of North America

Volumn 26, Issue 3, 2012, Pages 629-648

  Visentin, Michele ^a   Zhao, Rongbao ^a   Goldman, I David ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Antifolates; Folate receptor mediated endocytosis; Folate receptors; Methotrexate; Pemetrexed; Pralatrexate; Proton coupled folate transporter (PCFT); Reduced folate carrier (RFC)

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; AMINOPTERIN; CYCLOPHOSPHAMIDE; DIHYDROFOLATE REDUCTASE INHIBITOR; DIHYDROFOLIC ACID; FLUOROURACIL; FOLATE RECEPTOR 1; FOLATE RECEPTOR 2; FOLATE TRANSPORTER; FOLIC ACID; FOLIC ACID ANTAGONIST; FOLINIC ACID; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; ONYX 0801; PEMETREXED; PRALATREXATE; RALTITREXED; TETRAHYDROFOLIC ACID; THYMIDYLATE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW; BREAST CANCER; CANCER RESISTANCE; CUTANEOUS T CELL LYMPHOMA; DRUG EFFECT; DRUG MEGADOSE; DRUG SELECTIVITY; DRUG TARGETING; DRUG TRANSPORT; ENDOCYTOSIS; ENTERITIS; FOLATE METABOLISM; HUMAN; INFLAMMATORY DISEASE; INTESTINE; LEUKEMIA CELL LINE; LUNG NON SMALL CELL CANCER; LYMPHOMA; MEMBRANE TRANSPORT; MENINGEAL METASTASIS; MESOTHELIOMA; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PSORIASIS; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; TROPHOBLASTIC TUMOR; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; DRUG RESISTANCE, NEOPLASM; FOLIC ACID; FOLIC ACID ANTAGONISTS; HUMANS; METHOTREXATE; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84859955788     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2012.02.002     Document Type: Review

References (105)

1. Skipper H.E., Perry S. Kinetics of normal and leukemic leukocyte populations and relevance to chemotherapy. Cancer Res 1970, 30:1883-1897.
2. Goldin A., Venditti J.M., Humphreys S.R., et al. A quantitative comparison of the antileukemic effectiveness of two folic acid antagonists in mice. J Natl Cancer Inst 1955, 15:1657-1664.
3. Farber S., Diamond L.K., Mercer R.D., et al. Temporary remission in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl glutamic acid (aminopterin). N Engl J Med 1948, 238:787-793.
4. Goldman I.D., Chattopadhyay S., Zhao R., et al. The antifolates: evolution, new agents in the clinic, and how targeting delivery via specific membrane transporters is driving the development of a next generation of folate analogs. Curr Opin Investig Drugs 2010, 11:1409-1423.
5. Chattopadhyay S., Moran R.G., Goldman I.D. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 2007, 6:404-417.
6. Zhao R., Matherly L.H., Goldman I.D. Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev Mol Med 2009, 11:e4.
7. Matherly L.H., Hou Z. Structure and function of the reduced folate carrier A paradigm of a major facilitator superfamily mammalian nutrient transporter. Vitam Horm 2008, 79C:145-184.
8. Leamon C.P., Jackman A.L. Exploitation of the folate receptor in the management of cancer and inflammatory disease. Vitam Horm 2008, 79:203-233.
9. Xia W., Low P.S. Folate-targeted therapies for cancer. J Med Chem 2010, 53:6811-6824.
10. Zhao R., Diop-Bove N., Visentin M., et al. Mechanisms of membrane transport of folates into cells and across epithelia. Annu Rev Nutr 2011, 31:177-201.
11. Matherly L.H., Hou Z., Deng Y. Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev 2007, 26:111-128.
12. Qiu A., Jansen M., Sakaris A., et al. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 2006, 127:917-928.
13. Stokstad E.L. Historical perspective on key advances in the biochemistry and physiology of folates. Folic acid metabolism in health and disease 1990, 1-21. Wiley-Liss, New York. M.F. Picciano, E.L. Stokstad (Eds.).
14. Fujii K., Nagasaki T., Huennekens F.M. Accumulation of 5-methyltetrahydrofolate in cobalamin-deficient L1210 mouse leukemia cells. J Biol Chem 1982, 257:2144-2146.
15. Schramm V.L. Enzymatic transition states, transition-state analogs, dynamics, thermodynamics, and lifetimes. Annu Rev Biochem 2011, 80:703-732.
16. Zhao R., Goldman I.D. Resistance to antifolates. Oncogene 2003, 22:7431-7457.
17. Lowe K.E., Osborne C.B., Lin B.F., et al. Regulation of folate and one-carbon metabolism in mammalian cells. II. Effect of folylpoly-gamma-glutamate synthetase substrate specificity and level on folate metabolism and folylpoly-gamma-glutamate specificity of metabolic cycles of one-carbon metabolism. J Biol Chem 1993, 268:21665-21673.
18. Shane B. Folylpolyglutamate synthesis and role in the regulation of one-carbon metabolism. Vitam Horm 1989, 45:263-335.
19. Koizumi S., Ueno Y., Ohno I., et al. Reversal of methotrexate cytotoxicity to human bone marrow cells and leukemic K562 cells by leucovorin: methotrexate polyglutamates formation as a possible important factor. Jpn J Cancer Res 1990, 81:1162-1167.
20. Poser R.G., Sirotnak F.M., Chello P.L. Differential synthesis of methotrexate polyglutamates in normal proliferative and neoplastic mouse tissues in vivo. Cancer Res 1981, 41:4441-4446.
21. Fry D.W., Anderson L.A., Borst M., et al. Analysis of the role of membrane transport and polyglutamylation of methotrexate in gut and Ehrlich tumor in vivo as factors in drug sensitivity and selectivity. Cancer Res 1983, 43:1087-1092.
22. Fabre I., Fabre G., Goldman I.D. Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro. Cancer Res 1984, 44:3190-3195.
23. Zhao R., Min S.H., Qiu A., et al. The spectrum of mutations in the PCFT gene, coding for an intestinal folate transporter, that are the basis for hereditary folate malabsorption. Blood 2007, 110:1147-1152.
24. Diop-Bove N., Kronn D., Goldman I.D. Hereditary folate malabsorption [internet]. GeneReviews 1993-2008, University of Washington, Seattle, Seattle (WA). R.A. Pagon, T.D. Bird, C.R. Dolan (Eds.).
25. Zhao R., Gao F., Hanscom M., et al. A prominent low-pH methotrexate transport activity in human solid tumor cells: contribution to the preservation of methotrexate pharmacological activity in HeLa cells lacking the reduced folate carrier. Clin Cancer Res 2004, 10:718-727.
26. Desmoulin S.K., Wang L., Hales E., et al. Therapeutic targeting of a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate to human solid tumors based on selective uptake by the proton-coupled folate transporter. Mol Pharmacol 2011, 80:1096-1107.
27. Zhao R., Qiu A., Tsai E., et al. The proton-coupled folate transporter (PCFT): impact on pemetrexed transport and on antifolate activities as compared to the reduced folate carrier. Mol Pharmacol 2008, 74:854-862.
28. Zhao R., Hanscom M., Chattopadhyay S., et al. Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier; association with the presence of a secondary transport pathway. Cancer Res 2004, 64:3313-3319.
29. Volk E.L., Schneider E. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 2003, 63:5538-5543.
30. Kruh G.D., Belinsky M.G. The MRP family of drug efflux pumps. Oncogene 2003, 22:7537-7552.
31. Assaraf Y.G. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updat 2006, 9:227-246.
32. Schoenbach E.B., Greenspan E.M., Colsky J. Reversal of aminopterin and amethopterin toxicity by citrovorum factor. J Am Med Assoc 1950, 144:1558-1560.
33. Djerassi I. Methotrexate infusions and intensive supportive care in the management of children with acute lymphocytic leukemia: follow-up report. Cancer Res 1967, 27:2561-2564.
34. Hryniuk W.M., Bertino J.R. Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates. J Clin Invest 1969, 48:2140-2155.
35. Pratt C.B., Roberts D., Shanks E.C., et al. Clinical trials and pharmacokinetics of intermittent high-dose methotrexate-" leucovorin rescue" for children with malignant tumors. Cancer Res 1974, 34:3326-3331.
36. Allegra C.J., Chabner B.A., Drake J.C., et al. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 1985, 260:9720-9726.
37. Allegra C.J., Drake J.C., Jolivet J., et al. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci U S A 1985, 82:4881-4885.
38. Allegra C.J., Fine R.L., Drake J.C., et al. The effect of methotrexate on intracellular folate pools in human MCF-7 breast cancer cells. Evidence for direct inhibition of purine synthesis. J Biol Chem 1986, 261:6478-6485.
39. Baggott J.E., Vaughn W.H., Hudson B.B. Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5'-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J 1986, 236:193-200.
40. Matherly L.H., Barlowe C.K., Phillips V.M., et al. The effects of 4-aminoantifolates on 5-formyltetrahydrofolate metabolism in L1210 cells. J Biol Chem 1987, 262:710-717.
41. Matherly L.H., Barlowe C.K., Goldman I.D. Antifolate polyglutamylation and competitive drug displacement at dihydrofolate reductase as important elements in leucovorin rescue in L1210 cells. Cancer Res 1986, 46:588-593.
42. Treon S.P., Chabner B.A. Concepts in use of high-dose methotrexate therapy. Clin Chem 1996, 42:1322-1329.
43. Widemann B.C., Adamson P.C. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006, 11:694-703.
44. Gaynon P.S., Angiolillo A.L., Carroll W.L., et al. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group report. Leukemia 2010, 24:285-297.
45. Chamberlain M.C. Leptomeningeal metastasis. Semin Neurol 2010, 30:236-244.
46. Jaffe N. Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat Res 2009, 152:239-262.
47. Savage P., Seckl M., Short D. Practical issues in the management of low-risk gestational trophoblast tumors. J Reprod Med 2008, 53:774-780.
48. Colleoni M., Cole B.F., Viale G., et al. Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol 2010, 28:2966-2973.
49. Gennari A., Sormani M.P., Pronzato P., et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 2008, 100:14-20.
50. Salliot C., van der H.D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009, 68:1100-1104.
51. Schwartz D., Ferguson J.R. Current pharmacologic treatment paradigms for inflammatory bowel disease and the potential role of granulocyte/monocyte apheresis. Curr Med Res Opin 2007, 23:2715-2728.
52. Braus N.A., Elliott D.E. Advances in the pathogenesis and treatment of IBD. Clin Immunol 2009, 132:1-9.
53. Kalb R.E., Strober B., Weinstein G., et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009, 60:824-837.
54. Chen M., Kallenberg C.G. ANCA-associated vasculitides-advances in pathogenesis and treatment. Nat Rev Rheumatol 2010, 6:653-664.
55. Sharaf P.H., Yazici Y. Necrotizing vasculitis-a 2009 update. Bull NYU Hosp Jt Dis 2009, 67:303-305.
56. Matloub Y., Bostrom B.C., Hunger S.P., et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2011, 118:243-251.
57. Abramson J.S., Hellmann M., Barnes J.A., et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer 2010, 116:4283-4290.
58. Asselin B.L., Devidas M., Wang C., et al. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). Blood 2011, 118:874-883.
59. DeGraw J.I., Colwell W.T., Piper J.R., et al. Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin. J Med Chem 1993, 36:2228-2231.
60. Krug L.M., Ng K.K., Kris M.G., et al. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clin Cancer Res 2000, 6:3493-3498.
61. Wang E.S., O'Connor O., She Y., et al. Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 2003, 44:1027-1035.
62. O'Connor O.A., Horwitz S., Hamlin P., et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 2009, 27:4357-4364.
63. O'Connor O.A., Hamlin P.A., Portlock C., et al. Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 2007, 139:425-428.
64. Habeck L.L., Mendelsohn L.G., Shih C., et al. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs. Mol Pharmacol 1995, 48:326-333.
65. Jackman A.L., Taylor G.A., Gibson W., et al. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 1991, 51:5579-5586.
66. Cocconi G., Cunningham D., Van Cutsem E., et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol 1998, 16:2943-2952.
67. Popov I., Carrato A., Sobrero A., et al. Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). Eur J Cancer 2008, 44:2204-2211.
68. Kempin S., Gutierrez J., Wilson E., et al. Raltitrexed (Tomudex): an alternative choice in patients intolerant to 5-fluorouracil. Cancer Invest 2002, 20:992-995.
69. Shih C., Chen V.J., Gossett L.S., et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997, 57:1116-1123.
70. Taylor E.C., Kuhnt D., Shih C., et al. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2, 3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 1992, 35:4450-4454.
71. Wang Y., Zhao R., Goldman I.D. Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier. Clin Cancer Res 2004, 10:6256-6264.
72. Chattopadhyay S., Zhao R., Krupenko S.A., et al. The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line. Mol Cancer Ther 2006, 5:438-449.
73. Racanelli A.C., Rothbart S.B., Heyer C.L., et al. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res 2009, 69:5467-5474.
74. Rothbart S.B., Racanelli A.C., Moran R.G. Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas. Cancer Res 2010, 70:10299-10309.
75. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
76. Hanna N., Shepherd F.A., Fossella F.V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
77. Scagliotti G.V., Parikh P., Von Pawel J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
78. Ciuleanu T., Brodowicz T., Zielinski C., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432-1440.
79. Andreassi J.L., Moran R.G. Mouse folylpoly-gamma-glutamate synthetase isoforms respond differently to feedback inhibition by folylpolyglutamate cofactors. Biochemistry 2002, 41:226-235.
80. Zhao R., Gao F., Goldman I.D. Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem Pharmacol 2001, 61:857-865.
81. Chattopadhyay S., Tamari R., Min S.H., et al. Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability. Oncologist 2007, 12:808-815.
82. Niyikiza C., Baker S.D., Seitz D.E., et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002, 1:545-552.
83. Scagliotti G.V., Shin D.M., Kindler H.L., et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003, 21:1556-1561.
84. Assaraf Y.G. Molecular basis of antifolate resistance. Cancer Metastasis Rev 2007, 26:153-181.
85. Zhang D., Ochi N., Takigawa N., et al. Establishment of pemetrexed-resistant non-small cell lung cancer cell lines. Cancer Lett 2011, 309:228-235.
86. Hanauske A.R., Eismann U., Oberschmidt O., et al. In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Invest New Drugs 2007, 25:417-423.
87. Mauritz R., Peters G.J., Priest D.G., et al. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Biochem Pharmacol 2002, 63:105-115.
88. Zhao R., Zhang S., Hanscom M., et al. Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis. Clin Cancer Res 2005, 11:1294-1301.
89. Kamen B.A., Smith A.K. A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. Adv Drug Deliv Rev 2004, 56:1085-1097.
90. Salazar M.D., Ratnam M. The folate receptor: what does it promise in tissue-targeted therapeutics?. Cancer Metastasis Rev 2007, 26:141-152.
91. Parker N., Turk M.J., Westrick E., et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005, 338:284-293.
92. Puig-Kroger A., Sierra-Filardi E., Dominguez-Soto A., et al. Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. Cancer Res 2009, 69:9395-9403.
93. Reddy J.A., Dorton R., Westrick E., et al. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res 2007, 67:4434-4442.
94. Leamon C.P., Reddy J.A., Vlahov I.R., et al. Preclinical antitumor activity of a novel folate-targeted dual drug conjugate. Mol Pharm 2007, 4:659-667.
95. Li J., Sausville E.A., Klein P.J., et al. Clinical pharmacokinetics and exposure-toxicity relationship of a folate-vinca alkaloid conjugate EC145 in cancer patients. J Clin Pharmacol 2009, 49:1467-1476.
96. Dosio F., Milla P., Cattel L. EC-145, a folate-targeted vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers. Curr Opin Investig Drugs 2010, 11:1424-1433.
97. Fisher R.E., Siegel B.A., Edell S.L., et al. Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors. J Nucl Med 2008, 49:899-906.
98. Reddy J.A., Xu L.C., Parker N., et al. Preclinical evaluation of (99m)Tc-EC20 for imaging folate receptor-positive tumors. J Nucl Med 2004, 45:857-866.
99. van Dam G.M., Themelis G., Crane L.M., et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nat Med 2011, 17:1315-1319.
100. Gibbs D.D., Theti D.S., Wood N., et al. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Res 2005, 65:11721-11728.
101. Desmoulin S.K., Wang Y., Wu J., et al. Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors. Mol Pharmacol 2010, 78:577-587.
102. Wang L., Desmoulin S.K., Cherian C., et al. Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits beta-glycinamide ribonucleotide formyltransferase. J Med Chem 2011, 54:7150-7164.
103. Helmlinger G., Yuan F., Dellian M., et al. Interstitial pH and pO2 gradients in solid tumors in vivo: high- resolution measurements reveal a lack of correlation. Nat Med 1997, 3:177-182.
104. Stubbs M., Rodrigues L., Howe F.A., et al. Metabolic consequences of a reversed pH gradient in rat tumors. Cancer Res 1994, 54:4011-4016.
105. Raghunand N., Altbach M.I., van Sluis R., et al. Plasmalemmal pH-gradients in drug-sensitive and drug-resistant MCF-7 human breast carcinoma xenografts measured by 31P magnetic resonance spectroscopy. Biochem Pharmacol 1999, 57:309-312.